<DOC>
	<DOCNO>NCT02485067</DOCNO>
	<brief_summary>The primary purpose study assess efficacy safety THVD-201 ( Combination tolterodine pilocarpine ) patient Overactive bladder period treatment , 12 week . This study also include open label extension period additional 12 week follow treatment assess long-term efficacy safety THVD-201 patient Overactive bladder .</brief_summary>
	<brief_title>Clinical Study Assess Efficacy Safety THVD-201 Patients With OAB</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<mesh_term>Tolterodine Tartrate</mesh_term>
	<mesh_term>Pilocarpine</mesh_term>
	<criteria>20 85 year History OAB ( pure urge mixed urinary incontinence predominant urge incontinence ) ≥ 6 month . In case female , least 2 year pass since menopause . Or premenopausal female subject must use highly effective method birth control study . Subject childbearing potential must negative pregnancy test prior enrollment . Predominate stress incontinence , insensate incontinence ( incapable distinguish discrete incontinence episode ) overflow incontinence , major reason urine loss urinary frequency determine investigator . History neurogenic bladder . PVR &gt; 200mL History clinically significant renal disease estimate creatinine clearance define Cockcroft Gault formula &lt; 30 mL/min . History malignant tumor within past 5 year . History presence tachyarrhythmia cardiac disease opinion investigator might confound result study pose additional risk subject . Subjects value QTc &gt; 450 msec Screening visit . Patient asthma PSA ≥ 10 ng/mL male 50 year .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Overactive Bladder</keyword>
	<keyword>Tolterodine ( Detrusitol )</keyword>
	<keyword>Pilocarpine</keyword>
</DOC>